Sodium valproate improves sensorimotor gating deficit induced by sleep-deprivation in low doses

Abstract

Background/aim: Sleep-deprivation disrupts prepulse inhibition of acoustic startle reflex and can be used to mimic psychosis in experimental animals. On the other hand, it is also a model for other disorders of sensory processing including migraine. The aim of this study is to assess the effects of sodium valproate, a drug that is used in a variety of neuropsychiatric disorders, on normal and disrupted sensorimotor gating in rats.

Materials and methods: 62 Wistar Albino rats were randomly distributed into 8 groups. Subchronic and intraperitoneal sodium valproate were administrated to the sleep-deprived and non-sleep-deprived rats by either in 50-100 or 200 mg/kg/day. Prepulse inhibition test and locomotor activity test were performed. Sleep-deprivation induced by the modified multiple platform method.

Results: Sleep-deprivation impaired prepulse inhibition, decreased startle amplitude and increased locomotor activity. Sodium valproate did not significantly alter prepulse inhibition and locomotor activity in non-sleep-deprived and sleep-deprived groups. On the other hand, all doses decreased locomotor activity in drug treated groups, and low dose improved sensorimotor gating and startle amplitude after sleep-deprivation.

Conclusion: Low dose sodium valproate improves sleep-deprivation-disrupted sensorimotor gating, and this finding may rationalize the use of sodium valproate in psychotic states and other disorders of sensory processing. Dose-dependent effects of sodium valproate on sensorimotor gating should be investigated in detail.

Key words: Sleep deprivation, sodium valproate, prepulse inhibition, sensorimotor gating, psychosis, rat
1. **Introduction**

To model psychotic disorders in experimental animals, neurodevelopmental, pharmacological, lesion and genetic manipulation methods are frequently utilized. However, there is still no animal model where psychosis can be reflected by its all aspects. Sleep deprivation (SD) may be a valid psychosis model due to its effects on behavioral, neurochemical and neurophysiological parameters.

It was reported that, with SD, cognitive, perceptual and behavioral symptoms of psychosis in people and behavioral symptoms of psychosis in animals were observed [1, 2]. Psychosis-like behaviors such as hyperactivity, irritability, aggression, perseverative behaviors and increased response to psychostimulants are observed in rodents as a result of long-term SD [2, 3]. Schizophrenia and SD seem to be causing similar functional connectivity anomalies [4-6], neurophysiological [7-11] and neurochemical anomalies [12-16] in the brain. Moreover, the fact that the thalamic reticular nucleus (TRN), which is assumed to have a role in schizophrenia, is the place where the sleep spindles observed in electroencephalography are produced during NREM sleep, as well as evidence showing a decrease in the numbers and intensities of sleep spindles in non-medicated schizophrenia patients, their first-degree relatives and SD-applied healthy individuals [17-19], indicates possible common neurophysiological processes between SD and schizophrenia. For all these reasons, SD may be an ideal model to trigger a schizophrenia-like psychosis picture in experimental animals not only because it induces psychosis-like symptoms on the behavioral dimension, but also because it probably partially imitates psychosis-related neurophysiological and neurochemical mechanisms.

Furthermore, with SD, the prepulse inhibition (PPI) test is disrupted in humans and animals [20, 21]. As known, PPI refers to inhibition of the startle response by a weaker
stimulus that does not lead to startling that comes before a strong sensory stimulus that leads to startling [22]. The phenomenon of PPI that is seen in all mammals is a relatively constant neurobiological marker [23], and it is used as a measurement of sensorimotor gating [24]. It is accepted that agents that reverse the PPI that is disrupted in schizophrenia have a therapeutic potential. Usage of SD as a psychosis model was proposed as it disrupts PPI in both humans and animals [25].

On the other hand, dysregulation of sensory processing is suggested in several neurological disorders such as migraine. Migraine is characterized with the central sensitization of the trigemino-thalamic pathway that results in a sensitivity to certain modalities of sensorial input [26], and somatosensory gating is thought to be altered [27, 28]. Hence, SD is used as an experimental model for migraine [29] or for other disorders of sensory processing such as mania [30].

This study aimed to investigate the effect of sodium valproate (SVA), a widely used antiepileptic/mood stabilizer (MS) drug in several neuropsychiatric disorders, on sensorimotor gating in sleep-deprived and non-sleep-deprived rats. The effects of SVA on post-SD sensorimotor gating have not been assessed before. Here, 72-hour SD was used to mimic psychosis via disruption of prepulse inhibition and effects of SVA, an add-on treatment in psychotic disorders, on this model were investigated by using the PPI test and locomotor activity test.

2. Materials and methods

2.1. Animals and laboratory

All experiments were performed at the Neuropsychopharmacology Application and Research Center (NPARC) of Üsküdar University. 14-16-week-old 62 Wistar albino male rats were randomized into a total of eight groups including 4 groups without SD (non-
sleep deprivation; NSD) and 4 groups with SD. Two groups had 7 rats while others had
8 rats each. Both the NSD and SD groups consisted of vehicle groups and SVA-
administrated groups with doses of 50 mg/kg/day, 100 mg/kg/day and 200 mg/kg/day.
Injections were made intraperitoneally for 4 days 2 times a day as in the morning and
evening, and after the last injection in the morning of the 5th day, the experiments were
started.
Throughout the experiment, the animals were kept at a suitable room temperature (22 ±
2°C), 40-45% humidity, 12 hours of light/dark cycles (light in the period of 07:00-19:00),
and in a way that they would have access to food and water ad libitum. The subjects on
which SD was applied were housed in a water tank for 72 hours. The summary of the
experimental protocol may be seen in Table 1.

2.2. Ethical issues
This study was carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health, USA,
which was published and released in 1996. The protocol was approved by the Local Ethics
Committee of Üsküdar University on June 23, 2016 with the approval number of 2016-
13.

2.3. Drug
This study used the 400 mg/4 ml intravenous form of SVA (Depakin®, Sanofi-Aventis,
France) that is parenterally applied in humans, and each vial contained 400 mg of SVA.
As the drug could be used intraperitoneally in experimental animals [31], it was applied
in each injection by dissolving in 0.5 ml of saline. In the vehicle groups, each injection
contained only 0.5 ml of saline.

2.4. Prepulse inhibition test
For measurement of the PPI of the acoustic startle reflex, an SR-LAB Startle Response System (San Diego Instruments, San Diego, California, USA) was used. The device for the PPI test consisted of four isolation cabinets, software, control unit and animal enclosures. All animals were handled for 3 days prior to the start of the experiments to prevent anxiety, fear and/or stress of rats that could impair the startle response [32]. The rats were placed into the Plexiglas cylinders of the cabinets for 15 min for adaptation 24 hours before the test. On the test day, the test protocol was applied. PPI% was defined as a decrease in the amplitude of the startle reflex in the presence of a prepulse stimulus and calculated for each of the three different prepulse intensities by using the following formula: 

$$PPI\% = \left(1 - \frac{\rho_+}{\rho_-}\right) \times 100,$$

where $\rho_+$ is the startle amplitude with the prepulse, and $\rho_-$ is the startle amplitude without the prepulse. After each session, the chambers were cleaned with ethanol. In order to prevent the habituation of the animal, intersession intervals were at least one week [33].

2.4.1. Test protocol: The animals that were handled by the researcher for the first 3 days (D1-3) before the test were kept in the measurement boxes without stimulation for 15 min for their getting used to the device on D4, and the PPI test was ran on D5. This test starts by the habituation step lasting for 5 min where no stimulation is given, and only the background sound is present. In the following step, five 120 dB auditory stimuli are given. The blocks of stimuli are then consecutively repeated for eight times. In each of these blocks, five different auditory stimuli with randomly changing orders are applied with random intervals (varying between 10 and 30 s). These are:

1. 40-ms 120 dB auditory stimulus,
2. 40-ms 120 dB auditory stimulus 100 ms after a 20-ms basal + 4 dB pre-stimulus,
3. 40-ms 120 dB auditory stimulus 100 ms after a 20-ms basal + 8 dB pre-stimulus,
4. 40-ms 120 dB auditory stimulus 100 ms after a 20-ms basal + 16 dB pre-stimulus,

5. Background sound only (this stimulus is for controlling responses arising from the movement of the rat within the cage).

Finally, 5 startle stimuli given at the beginning of the measurement are applied again in random intervals (10-30 s), and the startle response is assessed. The entire protocol lasts approximately 26 min.

2.5. **Locomotor activity test**

The locomotor activity (LMA) test was carried out in an open-field activity monitoring system with nine sound-insulated chambers with dimensions of 40 × 40 × 30 cm (MAY 9908, Commat Ltd., Ankara, Turkey). The activity of the subjects was monitored and analyzed by an automated video-tracking device and software (Noldus, Ethovision v3.1, Netherlands). LMA was measured by determining the amount of “total distance moved” for the 30-minute-long test period.

2.6. **Modified multiple platform technique**

SD induction by this technique is dependent on that, when rats that are forced to stand on small platforms placed into a water-filled tank enter REM sleep, their muscles lose tone, their tails contact the water, and thus, they awaken from REM sleep. While it is usually reported that this mainly induces SD unique to the REM stage of sleep, studies have stated that it also affects the NREM stage at rates reaching about 40% [34]. Upon understanding that this technique induces anxiety in animals, it was proposed that this anxiety could be reduced by testing animals living in the same cage together [35] and allowing them to freely move among multiple platforms placed into the tank [36]. This way, the technique was modified in a way to allow the animals to be tested together and by moving. In different studies in the literature, tanks were used in different dimensions [37, 38]. In this
study, to trigger SD, a Plexiglas water tank with dimensions of 125 × 43 × 45 cm was used. Inside the tank, 14 platforms with a diameter of 6.5 cm and height of 16 cm each were placed so that they would have a distance of 10 cm from each other. The water tank was filled with water until the last 1 cm of the platforms, that is, at a height of 15 cm. The water temperature was adjusted at 23 ± 1°C. The tank was covered with grills that allowed access to water and food like in the cages. The animals of an entire group were put into the tank simultaneously.

2.7. Statistics

The statistical analysis of the data was performed using the PSPP Statistical Analysis Software 1.2.0 (GNU, Boston, MA) and RStudio 1.3.1093 (RStudio, PBC, Boston, MA). As the hypothesis of normal distribution (Shapiro-Wilk test) was rejected non-parametrical tests were used for the statistical analysis. The effects of drug treatment and SD on PPI% were analyzed using F1F1 function of R Program nparLD package, a non-parametrical test for mixed analysis of variance with repeated measures, where drug treatment or SD were the whole-plot factors and prepulse intensity was the repeated one. We reported ANOVA-type statistics (ATS). Kruskal-Wallis test was used to compare the basal mean PPI% among all groups, and startle amplitude and total distance moved values of SVA treated NSD or SD groups. Mann-Whitney U test was used to compare startle amplitude and total distance moved values of vehicle groups. A value of P < 0.05 was considered statistically significant.

3. Results

A non-significant difference between the basal mean PPI% of all groups indicates that the groups are similar in terms of the basal mean PPI% [X² (7) = .66, p = .99 > .05]. All
data including the basal mean PPI%, mean PPI%, startle amplitude and total distance moved are shown in Table 2. The weights of the subjects are shown in Table 3.

### 3.1. SVA effects in NSD groups

Figure 1 shows the effects of SVA on PPI% with 74 dB, 78 dB and 86 dB prepulses, respectively. The nparLD F1F1 test revealed a significant main effect of prepulse intensity on PPI% \([\text{ATS}}(1.72)= 101.00, p= .00 < .05\), a non-significant main effect of SVA on PPI% \([\text{ATS}}(2.83)= 1.30, p=.27 > .05\) and a non-significant effect of interaction \([\text{ATS}}(4.71)= .44, p=.80 > .05\]. There was no significant effect of SVA in the NSD groups on the startle values \((X^2 (3)= 6.32, p=.09 > .05\) (Figure 2) or the total distance moved (LMA) values \((X^2 (3)= 3.46, p=.32 > .05\) (Figure 3).

### 3.2. SD effects

Figure 4 shows the effects of SD on PPI% with 74 dB, 78 dB and 86 dB prepulses, respectively. The nparLD F1F1 test revealed a significant main effect of prepulse intensity on PPI% \([\text{ATS}}(1.91)= 34.23, p= .00 < .05\), a significant effect of SD on PPI% \([\text{ATS}}(1.00)= 5.61, p=.01 < .05\) and a non-significant effect of interaction \([\text{ATS}}(1.91)= 2.48, p=.08 > .05\]. There was a significant difference between the startle values of the SD vehicle (mdn= 44.90) and vehicle (mdn= 84.25) groups \([U= 11, z= -2.21, p= .02 < .05\) (Figure 5). There was a significant difference between the total distance moved values of the SD vehicle (mdn= 977.86) and vehicle (mdn= 683.31) groups \([U= 7, z= -2.63, p=.00 < .05\) (Figure 6).

### 3.3. SVA effects in SD groups

Figure 7 shows the effects of SVA in the SD groups on PPI% with 74 dB, 78 dB and 86 dB prepulses, respectively. The nparLD F1F1 test revealed a significant main effect of prepulse intensity on PPI% \([\text{ATS}}(1.96)= 35.64, p= .00 < .05\), a non-significant effect of
SVA on PPI% [ATS (2.91)= 1.16, p=.32 > .05] and a non-significant effect of interaction [ATS (5.01)= .59, p=.70 > .05]. There was a significant effect of SVA in the SD groups on the startle values [$X^2 (3)= 9.20$, p=.02 < .05] (Figure 8). Mann-Whitney U test revealed a significant difference between vehicle (mdn= 44.90) and SVA 50 mg/kg/day group (mdn= 119.90) [$U= 13.00$, z= -2.00, p=.04 < .05]. There was also a non-significant effect of SVA on the total distance moved values [$X^2 (3)= 7.59$, p=.055 > .05] (Figure 9).

4. Discussion

This study firstly showed that SVA did not have a statistically significant effect on the PPI%, startle and LMA in the rats at the subchronic intraperitoneal doses of 50-100 and 200 mg/kg/day. Secondly, it was shown that 72-hour SD significantly disrupted the PPI, decreased the startle, but increased the LMA in the rats. Afterwards, it was determined that the SVA application at the same doses did not have a statistically significant effect on the disrupted PPI and increased LMA by SD. On the other hand, SVA 50 mg/kg/day administration after SD significantly increased startle amplitude.

The main treatment of the condition of schizophrenia is achieved by antipsychotic drugs, while polypharmacy practices where MSs are added to existing antipsychotic treatments are very common. As there are few data supporting SVA usage in schizophrenia treatment, the usage of the drug is off-label, but its usage for this indication is prevalent [39]. According to studies, the frequency of adding SVA to schizophrenia treatment varies in the range of 15-50% [40]. The reason for using SVA in schizophrenia patients is frequently associated with achieving impulse control and reducing aggression in patients that do not respond to classical treatment [40]. There are studies suggesting that SVA reduces aggression in schizophrenia patients. For example, it was shown that SVA reduces aggression in schizophrenia patients receiving risperidone or olanzapine...
treatment [41]. The effectiveness of SVA, which is a GABAergic drug, in schizophrenia, which is a disorder that is considered to be characterized by mesolimbic dopamine increase, is associated with its reduction of dopaminergic activity [42].

As known, PPI is disrupted in several psychiatric disorders, especially schizophrenia. It is accepted that drugs that are shown to reverse this disruption have an antipsychotic potential. In addition to this, little is known about the action mechanisms of MSs on PPI. A study conducted in 2006 by Umeda et al. [43] investigated the effects of MSs on PPI disrupted by apomorphine and MK-801 in mice. Accordingly, it was seen that valproate (30-300 mg/kg, i.p.) did not have any effect on PPI by itself, but it reversed the PPI disruption caused by apomorphine (1 mg/kg, s.c.), and as it did not induce any effect on the PPI disrupted by dizocilpine (0.3 mg/kg, s.c.), it was thought that it induces its effect through the dopaminergic system. Again, in rodent models, it was reported that valproate (100 mg/kg) did not have an effect on PPI disruption induced by ketamine or amphetamine [44]. In an epigenetic schizophrenia mouse model induced by methionine, it was determined that valproate (1.5 mmol/kg) did not have an effect by itself on PPI, but when used together, it antagonized the reduction in PPI created by methionine [45].

Similar to the aforementioned studies, in this study, it was also shown that SVA did not have a significant effect on the PPI at the tested doses. However, although the difference was not statistically significant, SVA reduced the LMA at all doses that were used. It is expected that the LMA of rodents would decrease in the open field test in relation to anxiety [46]. Furthermore, many studies reported the anxiolytic properties of SVA [47, 48]. For this reason, observation of a decrease in the LMA in this study by SVA was not an expected effect. However, it was considered that the known sedation effect of SVA [49] could have reduced the LMA.
SD, which was applied at the second stage of the study, behaviorally induces a psychosis-like picture without any pharmacological intervention. It was reported that, in humans, anxiety, irritability and perceptual distortions start by 24-48 hours of SD, thought disorders and hallucinations are seen in 48-90 hours, and delusions emerge after 72 hours [50]. As this psychosis-like picture emerges after 48 hours, in this study, the rats were subjected to SD for 72 hours. The disruption of the sensorimotor gating and presence of hyperactivity in the rats after SD indicate that the model may be used as a psychosis model in experimental animals.

It was observed that SVA, which started to be applied 24 hours before 72-hour SD and continued for a total of 4.5 days, did not create a statistically significant effect on the PPI% at doses of 50-100 and 200 mg/kg/d. However, although the difference was not significant, the 50 mg/kg/day form of SVA increased the already reduced PPI% at all prepulses, while the other doses appeared to reduce it even more. Likewise, at the applied doses, while SVA did not have a statistically significant effect on LMA, it appeared to reduce the LMA increased by SD (p = .057). At this point SVA 50 mg/kg/day was the only dose reducing the LMA most and it also significantly normalized the decreased startle amplitude levels by SD.

Considering animal models, the positive effects of SVA on sensorimotor gating are reported. In a schizophrenia mouse model, it was reported that SVA applied prophylactically for 14 days at 200 mg/kg 2×1 prevented PPI deficits and hyperactivity [51]. Another study showed that SVA acutely applied at the doses of 178-316 mg/kg increased the PPI% of mice that had naturally low PPI [52]. Similarly, there are also studies and case reports suggesting that SVA reduces psychotic symptoms in schizophrenia when it is added to an ongoing antipsychotic treatment. It was reported that
addition of 1700 mg/day of SVA to the treatment of a patient with functional hallucinations receiving antipsychotic treatment improved hallucinations and noticeably increased the functionality of the patient [53]. A double-blind randomized study determined that addition of SVA by about 2300 mg to the treatment of olanzapine or risperidone at acute exacerbation of schizophrenia achieved a reduction in psychotic symptoms by using PANSS and BPRS [54]. In an open-label study where SVA was added at a mean dose of 1600 mg/day to the treatments of 28 schizophrenia patients with long disease durations, it was reported that 9 of the patients responded well to the treatment, 12 responded partially, and 7 did not respond or responded negatively (n= 2) [55]. Furthermore, in a review containing randomized controlled studies, it was reported that there is only limited evidence that SVA added to antipsychotic treatment improves the general clinical response, especially aggression [56]. Likewise, in a detailed review containing several studies, it was reported that adding SVA to the treatment in schizophrenia has a very limited benefit [57]. On the other hand, to the best of our knowledge, there are no broad-scaled studies reporting on the worsening effect of SVA on psychotic symptoms in psychotic patients. As in a study by Suzuki et al. [55], while it was noted that worsening was observed in schizophrenia patients who were given additional SVA treatment, diffuse negative effects were not mentioned. Probably for these reasons, the tendency of clinicians towards adding SVA to schizophrenia treatment is stronger.

On the other hand, low dose SVA (500-1000 mg/day) is used in prophylaxis of migraine [58]. Action mechanisms of SVA includes inhibition of voltage-dependent sodium channels and T-type calcium currents, potentiation of GABA concentrations via GABA-synthesizing and degrading enzymes, modulation of the extracellular signal-regulated
kinase pathway [59]. Consequently, it decreases neurogenic inflammation and prevents
central sensitization that are results of cortical spreading depression, a phenomenon that
has a prominent role in migraine pathophysiology [60].

In addition to that, it was showed that SVA prevents CSD mediated activation of TRN
[31], a GABAergic region within the thalamocortical circuit that has a role in sensory
gating that is suggested to dysfunction in schizophrenia and migraine [31, 5]. Hence, in
considering the positive effects of low dose SVA in both migraine treatment and
sensorimotor gating, future studies may focus on revealing how SVA acts on particular
brain regions related to sensorimotor gating. Also, low and high SVA was shown to have
different pharmacological effects in brain. It was reported that SVA effects GABA and
aspartate metabolism in low doses, and as dose rises it begins to increase serotonin and
other monoamine levels, decrease succinic semi-aldehyde dehydrogenase, decrease ATP
levels, inhibit sodium currents, increase glutamate release, modulate calcium and
potassium conductance, and inhibit GABA transaminase [61]. Therefore, it may be
suggested that positive effects of low dose SVA on sensorimotor gating following SD
arise from its effects on GABA, aspartate and/or monoamines, nevertheless dose-
dependent effects of SVA especially in brain regions involved in sensorimotor gating
should be investigated.

While it is not possible to completely adapt the data obtained in this study to humans, the
drug doses that were used in this study were based on the doses used in humans. In studies
with experimental animals, to determine the corresponding dose of drugs in humans, the
formula “Human equivalent dose (mg/kg) = Animal dose (mg/kg) × [Animal \( K_m \)/ Human
\( K_m \)]” is used [62]. \( K_m \) is the correction factor, whereas it is found by dividing the average
weight of the species (kg) by the body’s surface area (m\(^2\)). Accordingly, the SVA doses
that were used in this study corresponded to 567 mg/day, 1135 mg/day and 2270 mg/day for a 60 kg person. While the doses of SVA used in humans are adjusted based on plasma levels, they frequently vary in the range of 500-2500 mg. Therefore, in this study, SVA was used in a broad dose range to substantially reflect the clinical usage of the drug.

This study had some limitations. The plasma levels of SVA were not checked in the study, and as it is a parenteral medication application, it was assumed that it showed the known pharmacodynamic and pharmacokinetic effects. Moreover, in a similar study that has been conducted on rats before [63], authors determined that the plasma drug (gabapentin) levels were halved after SD. As the pharmacokinetic properties of drugs may vary with the effect of SD, it is possible that SVA levels could also be changed, but this possibility was not examined. Additionally, application of SVA for a longer time than that in this study may lead to observation of different effects. Another limitation was that the study did not use a sham group where the effects of the water tank could be assessed. Nevertheless, in previous SD studies conducted at our laboratory, the sole effect of the water tank was examined by using a sham group, and it was observed that the sensorimotor gating in this group did not change, but LMA increased by a bit, while it was not as noticeable as the increase in the SD group. With the purpose of using a smaller number of subjects, re-assessment of the sham effect was not considered necessary. The fact that two groups in the study included 7 rats rather than 8 was another limitation, and it may have affected the results.

This study where the effects of SVA on sensorimotor gating disrupted by SD were investigated is the first one in the literature to the best of our knowledge. In studies examining the effects of SVA, PPI was frequently disrupted by using pharmacological agents, and the effects of SVA on this disruption were then investigated. In this study, on
the other hand, the behavioral symptoms of psychosis were induced via SD and without using a pharmacological method. Although projecting data obtained from experimental animals directly onto humans would not be convenient, this study suggested that, in psychotic pictures, sole medium-high dose SVA usage may affect sensorimotor gating negatively, while low-dose usage may have a positive effect. This situation may indicate that the drug has dose-dependent effects on sensorimotor gating. Again, the fact that SVA shows sedative effects in a broad dose range may explain its clinical activity reported in psychotic pictures. It seems necessary to investigate the benefits and risks of using SVA in psychotic pictures in more detail. On the other hand, in persons with sensorimotor gating disorders that do not show explicit psychotic symptoms, usage of SVA for other reasons may have a possibility of triggering psychotic symptoms. In this sense, it may be necessary for clinicians to more strictly monitor especially patients with a history of psychiatric disorders in their family.

Source of funding: None declared.

References


13. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience 2005; 6 (4): 312-324. doi: 10.1038/nrn1648


54. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P et al. Effect of
    divalproex combined with olanzapine or risperidone in patients with an acute
    exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28 (1): 182-192. doi:
    doi.org/10.1038/sj.npp.1300023

55. Suzuki T, Uchida H, Takeuchi H, Nakajima S, Nomura K et al. Augmentation of
    atypical antipsychotics with valproic acid. An open-label study for most difficult patients
    with schizophrenia. Human Psychopharmacology Clinical and Experimental 2009; 24
    (8): 628-38. doi: 10.1002/hup.1073

56. Wang Y, Xia J, Helfer B, Li C, Leucht S. Valproate for schizophrenia. The
    Cochrane Database of Systematic Reviews 2016; 11: CD004028. doi:
    10.1002/14651858.CD004028.pub4

57. Citrome L. Adjunctive lithium and anticonvulsants for the treatment of
    55-71. doi: 10.1586/14737175.9.1.55

58. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J et al. A randomized trial
    of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;

    47-71. doi: 10.1016/S0072-9752(10)97004-8

60. Parikh SK, Silberstein SD. Current status of antiepileptic drugs as preventive
    migraine therapy. Current Treatment Options in Neurology 2019; 21 (4): 16. doi:
    10.1007/s11940-019-0558-1

61. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug

## Table 1. Experiment protocol

<table>
<thead>
<tr>
<th>NSD</th>
<th>Vehicle</th>
<th>Hour(s)</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>8</td>
<td>09:00</td>
<td>S/HC</td>
<td>S/HC</td>
<td>S/HC</td>
<td>S/HC</td>
<td>S/HC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
<td>S/HC</td>
<td>S/HC</td>
<td>S/HC</td>
<td>S/HC</td>
<td>-</td>
</tr>
<tr>
<td>SVA 50 mg/kg/day</td>
<td>7</td>
<td>09:00</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>-</td>
</tr>
<tr>
<td>SVA 100 mg/kg/day</td>
<td>8</td>
<td>09:00</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>-</td>
</tr>
<tr>
<td>SVA 200 mg/kg/day</td>
<td>7</td>
<td>09:00</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>SVA/H C</td>
<td>-</td>
</tr>
<tr>
<td>Vehicle</td>
<td>8</td>
<td>09:00</td>
<td>S/HC</td>
<td>S/WT</td>
<td>S/WT</td>
<td>S/WT</td>
<td>S/WT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
<td>S/HC</td>
<td>S/WT</td>
<td>S/WT</td>
<td>S/WT</td>
<td>-</td>
</tr>
<tr>
<td>SVA 50 mg/kg/day</td>
<td>8</td>
<td>09:00</td>
<td>SVA/H C</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
<td>SVA/H C</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SVA/H C</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>---</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td><strong>SVA 100 mg/kg/day</strong></td>
<td>8</td>
<td>09:00</td>
<td>SVA/H C</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SVA 200 mg/kg/day</strong></td>
<td>8</td>
<td>09:00</td>
<td>SVA/H C</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td>SVA/W T</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 NSD: non-sleep deprivation, SD: sleep deprivation, S: saline, SVA: sodium valproate,

2 HC: home cage, WT: water tank.
Table 2. Basal mean PPI%, mean PPI%, startle amplitude, and total distance moved values of all groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number of rats (n)</th>
<th>Basal mean PPI % ± s.d.</th>
<th>Mean PPI% ± s.d.</th>
<th>Startle amplitude ± s.d.</th>
<th>Total distance moved (cm) ± s.d.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>8</td>
<td>50.37 ± 14.74</td>
<td>51.86 ± 16.40</td>
<td>69.14 ± 11.70</td>
<td>78.55 ± 10.55</td>
</tr>
<tr>
<td>NS D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SVA 50 mg/kg/day</td>
<td>7</td>
<td>52.14 ± 15.72</td>
<td>59.86 ± 11.45</td>
<td>74.14 ± 6.73</td>
<td>82.32 ± 6.24</td>
</tr>
<tr>
<td>SVA 100 mg/kg/day</td>
<td>8</td>
<td>49.25 ± 15.12</td>
<td>56.27 ± 25.66</td>
<td>78.37 ± 9.93</td>
<td>85.46 ± 8.12</td>
</tr>
<tr>
<td>SVA 200 mg/kg/day</td>
<td>7</td>
<td>52.14 ± 10.31</td>
<td>57.67 ± 12.88</td>
<td>71.50 ± 10.76</td>
<td>75.30 ± 12.61</td>
</tr>
<tr>
<td></td>
<td>Vehicle</td>
<td>8</td>
<td>50.00 ± 13.86</td>
<td>41.58 ± 22.50</td>
<td>62.84 ± 27.46</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>---</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>SVA 50 mg/kg/day</td>
<td>8</td>
<td>52.87 ± 13.41</td>
<td>50.38 ± 25.94</td>
<td>69.90 ± 10.00</td>
<td>146.40 ± 105.42</td>
</tr>
<tr>
<td>SVA 100 mg/kg/day</td>
<td>8</td>
<td>54.25 ± 13.18</td>
<td>21.64 ± 31.95</td>
<td>56.59 ± 17.69</td>
<td>43.88 ± 33.63</td>
</tr>
<tr>
<td>SVA 200 mg/kg/day</td>
<td>8</td>
<td>52.75 ± 16.10</td>
<td>30.18 ± 28.77</td>
<td>45.89 ± 37.21</td>
<td>56.26 ± 92.89</td>
</tr>
</tbody>
</table>

NSD: non-sleep deprivation, SD: sleep deprivation, SVA: sodium valproate,

s.d.=standart deviation.
<table>
<thead>
<tr>
<th>Groups</th>
<th>Number of rats (n)</th>
<th>Weight ± s.d.</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSD</td>
<td>Vehicle</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>SVA 50 mg/kg/day</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>SVA 100 mg/kg/day</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>SVA 200 mg/kg/day</td>
<td>7</td>
</tr>
<tr>
<td>SD</td>
<td>Vehicle</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>SVA 50 mg/kg/day</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>SVA 100 mg/kg/day</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>SVA 200 mg/kg/day</td>
<td>8</td>
</tr>
</tbody>
</table>

NSD: non-sleep deprivation, SD: sleep deprivation, SVA: sodium valproate, s.d.=standart deviation.
Figure 1. Prepulse inhibition percentage across non-sleep deprivation groups for different prepulse intensities. PPI% values are different in different prepulse intensities (p< .05) (not denoted). SVA does not have a significant effect on PPI% (p> .05). Error bars represent standard deviations. NSD: non-sleep deprivation, SVA: sodium valproate, PPI: prepulse inhibition, dB: decibel.
Figure 2. Startle amplitude across non-sleep deprivation groups. SVA does not have a significant effect on startle amplitude (p > .05). Error bars represent standard deviations.

NSD: non-sleep deprivation, SVA: sodium valproate.
Figure 3. Total distance moved across non-sleep deprivation groups. SVA does not have a significant effect on total distance moved (p > .05). Error bars represent standard deviations. NSD: non-sleep deprivation, SVA: sodium valproate.
**Figure 4.** Prepulse inhibition percentage across vehicle groups for different prepulse intensities. PPI% values of NSD groups are different ($p < .05$) (not denoted). There are significant PPI% differences between vehicle and SD-vehicle groups with different prepulse intensities (denoted with *, $p < .05$). Error bars represent standard deviations. SD: sleep deprivation, PPI: prepulse inhibition, dB: decibel.
Figure 5. Startle amplitude across vehicle groups. SD has a significant effect on startle amplitude (denoted with *, \( p < .05 \)). Error bars represent standard deviations. SD: sleep deprivation.
Figure 6. Total distance moved across vehicle groups. SD has a significant effect on total distance moved (denoted with *, p< .05). Error bars represent standard deviations. SD: sleep deprivation.
Figure 7. Prepulse inhibition percentage across sleep deprivation groups for different prepulse intensities. PPI% values are different in different prepulse intensities (p< .05) (not denoted). SVA does not have a significant effect on PPI% with different prepulses (p > .05). Error bars represent standard deviations. SVA: sodium valproate, PPI: prepulse inhibition, dB: decibel.
Figure 8. Startle amplitude across sleep deprivation groups. SVA 50 mg/kg/day has a significant effect on startle amplitude compared to vehicle (denoted with *, p < .05). Error bars represent standard deviations. SVA: sodium valproate.
Figure 9. Total distance moved across sleep deprivation groups. SVA does not have a significant effect on total distance moved (p > .05). Error bars represent standard deviations. SVA: sodium valproate.